Yosemite, a San Francisco, CA-based cancer-focused venture capital firm, launched with $200m in funding.
Backers included MIT, Memorial Sloan Kettering Cancer Center and The Rockefeller University.
Led by 31-year old Reed Jobs, Yosemite appears to be an extension of the legacy left by the founder’s father, Steve Jobs, the co-founder of Apple, who died in 2011 from a rare form of pancreatic cancer at the age of only 56.
The firm will run as a for-profit business while also maintaining a donor-advised fund which will make grant money available to scientists.
In terms of targeting pancreatic cancer, the efforts align with the Pancreatic Cancer Action Network (PanCAN), which has been urging advocates from all 50 US states to call on Congress to increase federal funding for pancreatic cancer research.
Yosemite deploys capital from early non-profit grantees through late-stage companies to fund advancements across the oncology ecosystem. It leverages its scientific network to create and finance companies that drive the translation of new therapies in patients and optimize the patient experience. Yosemite aims to accelerate the technology, treatments, and standard of care that have the power to improve the health and lives of cancer patients.